Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Bausch & Lomb Corp (BLCO)
Bausch & Lomb Corp (BLCO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,876,518
  • Shares Outstanding, K 350,001
  • Annual Sales, $ 3,768 M
  • Annual Income, $ 6,000 K
  • 60-Month Beta N/A
  • Price/Sales 1.52
  • Price/Cash Flow 7.51
  • Price/Book 0.81
Trade BLCO with:
  • Price/Earnings ttm 15.29
  • Earnings Per Share ttm 1.07
  • Most Recent Earnings 0.23 on 02/22/23
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    SIC-3851 Ophthalmic Goods

    Medical Services

Options Overview Details

View History
  • Implied Volatility 45.64% ( +45.64%)
  • Historical Volatility 41.60%
  • IV Percentile 20%
  • IV Rank 58.21%
  • IV High 75.67% on 05/26/22
  • IV Low 3.81% on 12/08/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 34
  • Volume Avg (30-Day) 119
  • Put/Call OI Ratio 1.01
  • Today's Open Interest 5,320
  • Open Int (30-Day) 4,353

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate 0.14
  • Number of Estimates 6
  • High Estimate 0.19
  • Low Estimate 0.11
  • Prior Year 0.24
  • Growth Rate Est. (year over year) -41.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.21 +10.72%
on 03/15/23
18.05 -6.70%
on 03/01/23
-0.60 (-3.44%)
since 02/28/23
3-Month
14.81 +13.71%
on 12/30/22
19.17 -12.15%
on 02/15/23
+2.07 (+14.01%)
since 12/28/22

Most Recent Stories

More News
Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and Novaliq GmbH, a biopharmaceutical company...

BLCO : 16.84 (+0.30%)
BLCO.TO : 22.93 (+0.44%)
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results

Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better,...

BLCO : 16.84 (+0.30%)
BLCO.TO : 22.93 (+0.44%)
Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced the appointment...

BLCO : 16.84 (+0.30%)
BLCO.TO : 22.93 (+0.44%)
New Bausch + Lomb Social Media Campaign Highlights What ‘Sights’ Inspire AMD Patients

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced a new social media campaign...

BLCO : 16.84 (+0.30%)
BLCO.TO : 22.93 (+0.44%)
Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection)

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and Modulight Corporation (“Modulight”),...

BLCO : 16.84 (+0.30%)
BLCO.TO : 22.93 (+0.44%)
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2022 Financial Results on February 22

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year...

BLCO : 16.84 (+0.30%)
BLCO.TO : 22.93 (+0.44%)
Bausch + Lomb Acquires AcuFocus, Inc.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc. (“AcuFocus”), a privately...

BLCO : 16.84 (+0.30%)
BLCO.TO : 22.93 (+0.44%)
Bausch + Lomb Introduces Enhanced PreserVision® AREDS 2 Formula Mini Soft Gels with OCUSorb™

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of PreserVision...

BLCO : 16.84 (+0.30%)
BLCO.TO : 22.93 (+0.44%)
Bausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare Conference

Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, has published a company...

BLCO : 16.84 (+0.30%)
BLCO.TO : 22.93 (+0.44%)
Bausch + Lomb Announces Participation at the 41st Annual J.P. Morgan Healthcare Conference

Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced that Joseph C. Papa, chief...

BLCO : 16.84 (+0.30%)
BLCO.TO : 22.93 (+0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Bausch Lomb Corporation is an eye health company. Its product portfolio includes Biotrue(R) and renu(R) multi-purpose solutions, Biotrue(R) ONEday daily disposable contact lenses, LUMIFY(R) redness reliever eye drops, PreserVision(R) AREDS 2 formula eye vitamin and mineral supplements and VYZULTA(R)....

See More

Key Turning Points

3rd Resistance Point 17.32
2nd Resistance Point 17.19
1st Resistance Point 17.02
Last Price 16.84
1st Support Level 16.72
2nd Support Level 16.59
3rd Support Level 16.42

See More

52-Week High 20.20
Fibonacci 61.8% 17.14
Last Price 16.84
Fibonacci 50% 16.20
Fibonacci 38.2% 15.26
52-Week Low 12.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar